SPONSOR
Sichuan Baili Pharmaceutical Co., Ltd.
Total Trials
10
Recruiting
10
Phases
Phase 2, Phase 1, Phase 3, Phase 2, Phase 3
Conditions studied: Urinary System TumorSolid TumorRheumatoid ArthritisHER2-positive Breast CancerUrothelial CarcinomaRecurrent GlioblastomaBreast CancerLocally Advanced or Metastatic Solid TumorNon-squamous Non-small Cell Lung CancerMultiple Myeloma
Sichuan Baili Pharmaceutical Co., Ltd. is a clinical research sponsor with 10 registered studies on ClinicalTrials.gov, of which 10 are actively recruiting participants. Research covers conditions including Urinary System Tumor, Solid Tumor, Rheumatoid Arthritis, HER2-positive Breast Cancer.
The trial portfolio spans Phase 2, Phase 1, Phase 3 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Sichuan Baili Pharmaceutical Co., Ltd.
How many clinical trials has Sichuan Baili Pharmaceutical Co., Ltd. sponsored?
ClinicalMetric currently tracks 10 clinical trials sponsored by Sichuan Baili Pharmaceutical Co., Ltd., of which 10 are actively recruiting participants. These trials cover conditions including Urinary System Tumor, Solid Tumor, Rheumatoid Arthritis. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Sichuan Baili Pharmaceutical Co., Ltd. research focus on?
Sichuan Baili Pharmaceutical Co., Ltd. clinical trials span Urinary System Tumor, Solid Tumor, Rheumatoid Arthritis, HER2-positive Breast Cancer, Urothelial Carcinoma, and additional conditions. The research pipeline includes Phase 2, Phase 1, Phase 3 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Sichuan Baili Pharmaceutical Co., Ltd. clinical trial?
To participate in a Sichuan Baili Pharmaceutical Co., Ltd. trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Sichuan Baili Pharmaceutical Co., Ltd. trials with current recruitment status updated daily.
Clinical Trials by Sichuan Baili Pharmaceutical Co., Ltd.
NCT05785039 Phase 2
Recruiting
A Study of BL-B01D1 in Patients With Multiple Solid Tumors, Including Locally Advanced or Metastatic Urinary System Tumors
Urinary System Tumor
NCT06857227 Phase 1
Recruiting
A Study of GNC-038 Tetra-specific Antibody Injection in Patients With Rheumatoid Arthritis
Rheumatoid Arthritis
NCT06830889 Phase 3
Recruiting
A Study of BL-M07D1 Versus T-DM1 in the Adjuvant Treatment of HER2-positive Breast Cancer With Residual Invasive Cancer After Neoadjuvant Therapy
HER2-positive Breast Cancer
NCT06405425 Phase 2
Recruiting
A Study of BL-B01D1 + PD-1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
Urothelial Carcinoma
NCT06891833 Phase 2, Phase 3
Recruiting
A Study of BL-M07D1 With or Without Pertuzumab Versus Docetaxel + Carboplatin + Trastuzumab + Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer
HER2-positive Breast Cancer
NCT06598787 Phase 2
Recruiting
A Study of BL-B01D1 in Patients With Recurrent Glioblastoma
Recurrent Glioblastoma
NCT07753226 Phase 1
Recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors
Breast Cancer
NCT05461768 Phase 1
Recruiting
A Study of BL-M07D1 in Patients With Locally Advanced or Metastatic HER2-Positive/Negative Breast Cancer and Other Solid Tumors
Breast Cancer
NCT07264816 Phase 2
Recruiting
A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC
Non-squamous Non-small Cell Lung Cancer
NCT07255898 Phase 1
Recruiting
A Study of BL-M24D1 in Patients With Relapsed or Refractory Multiple Myeloma and Other Hematologic Malignancies
Multiple Myeloma
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology